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Abstract
Purpose: The aim of this study is to quantify and describe the feasibility, clinical outcomes, and
patient-reported outcomes of reduced planning target volume (PTV) margins for prostate cancer
treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency
transponder beacons.
Methods and materials: For this prospective, nonrandomized trial, the Calypso localization sys-
tem was used for intrafraction target localization in 31 patients with a PTV margin reduced to 2 mm
in all directions. A total of 1333 fractions were analyzed with respect to movement of the prostate,
pauses and interruptions, and dosimetric data. Pre- and posttreatment quality-of-life scores were
tracked at baseline, during treatment, and up to 24 months after treatment.
Results: The mean time of daily treatment was 10 minutes, with 96.1% of all treatments falling
within a 20-minute treatment window standard. On average, beacon motion exceeded 3 mm during
active treatment only 1.76% of the time. The average length of treatment interruption was 34.2
seconds, with an average of 1 interruption every 3.39 fractions. The displacement or excursion of
the prostate was the greatest in the superior or inferior dimension (0.11 mm and 0.09 mm,
respectively) and anterior or posterior dimension (0.07 mm and 0.13 mm, respectively), followed
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by the left or right dimension (0.05 mm and 0.06 mm, respectively). At 6 months, patients
demonstrated a smaller change in Expanded Prostate Cancer Index Composite scores than the
ProtecT comparator group (decreased short-term morbidity). However, in the Bowel and Urinary
domains at 12 and 24 months, there was no significant difference.
Conclusions: Our data confirm and support that the use of Calypso tracking with intensity
modulated radiation therapy reliably provides minimal disruption to daily treatments and overall
time of treatment, with the PTV only moving outside of a 3-mm margin < 2% of the time. The use
of a 3-mm PTV margin provides adequate dosimetric coverage while minimizing genitourinary and
gastrointestinal toxicity.
 2018 Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Radiation therapy is an effective treatment option for
many men with localized prostate cancer. The use of
advanced radiation techniques including intensity modu-
lated radiation therapy (IMRT) and volumetric modulated
arc therapy (VMAT) have been shown to reduce gastro-
intestinal (GI) and genitourinary (GU) toxicities, even in
the setting of dose escalation.1-3 The addition of daily
image guided radiation therapy (IGRT) has led to a
further reduction in the dose adjacent to organs at risk and
improved toxicity rates by reducing planning target vol-
ume (PTV) margins.4 Several systems have been devised
to more precisely localize the target compared with skin
markings, including daily ultrasound localization, cone
beam computed tomography (CBCT), and implanted
fiducial markers or gold seeds with daily orthogonal
pretreatment portal imaging. The implementation of these
methods have allowed for a reduction in PTV expansion
to 5 to 7 mm.5-7
In the past decade, there has been increasing research
into intrafraction motion of the prostate related to changes
in treatment planning, dosimetry, and radiation-associated
toxicities.8-20 However, PTV margins still vary widely
depending on immobilization and IGRT technique.
Recent protocols have mandated PTV margins of 5 to 10
mm, and only in the setting of extremely hypofractionated
radiation therapy (SBRT) have margins of <5 mm been
considered acceptable in most practices.21 Many in-
stitutions are now using a 5-mm posterior expansion in
the setting of IGRT with conventional fractionation. Real-
time electromagnetic tracking of the prostate allows for
the real-time tracking of internal organ and patient
movement, which can allow for a further decrease in PTV
margin. In theory, this would lead to a reduction in doses
to adjacent organs at risk and reduction in late toxicities.
The current study is a prospective trial using the
Calypso four-dimensional localization system to treat
patient volunteers with prostate cancer with a clinical
target volume to PTV margin of only 3 mm. We evaluated
the feasibility, clinical outcomes, and patient-reported
quality-of-life outcomes of reduced PTV margins for
prostate cancer treatments using real-time continuous
intrafraction monitoring with implanted radiation fre-
quency transponder beacons.
Methods and materials
Patient Population
Men with low or intermediate risk of prostate cancer
per the National Comprehensive Cancer Network risk
groups were treated with definitive IMRT using reduced
PTV margins in a prospective, single-institution, non-
randomized trial. The eligibility criteria included age >
40 years, histologically confirmed prostate adenocarci-
noma, cT1a-cT2c, Gleason score 7, prostate-specific
antigen 15, and Zubrod performance score of 0 or 1.
Patients with high risk (per the National Comprehensive
Cancer Network), node-positive, or metastatic disease
were excluded as well as patients with a history of con-
nective tissue or inflammatory bowel disease, active
implanted devices, or prior prostate cancer treatments
other than androgen deprivation therapy (ADT). Patients
with maximum anterioreposterior separation through the
torso minus the height of the center of the prostate >17
cm were excluded as well for technical reasons. We ob-
tained approval from our institutional review board and
ethics committee. Patients provided consent prior to
enrollment in this trial.
Treatment planning and margins
Three Calypso Beacon Transponders were implanted in
the prostate via rectal ultrasound guidance per the manu-
facturer’s instructions 4 to 7 days prior to computed to-
mography simulation. Computed tomography simulation
was performed with a full bladder and empty rectum (and
daily treatment), with coaching on behavioral and dietary
modifications to achieve these goals. Lower extremity Vac-
Lok bags were used for immobilization. The normal tissues
were contoured per theRadiation TherapyOncologyGroup
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guidelines. The gross tumor volume was defined as the
entire prostate. The apex was defined by either prostate
magnetic resonance imaging or urethrogram.
For men with low risk prostate cancer, the clinical
target volume (CTV) equaled the gross tumor volume
without expansion. For men with intermediate risk pros-
tate cancer, the CTV equaled the prostate, proximal 1 cm
of the seminal vesicles, plus a 3-mm expansion of the
prostate (minus rectum and bladder) to account for
possible extraprostatic extension. The PTV for all patients
was a 3-mm uniform expansion from the CTV. CBCT
was typically used once weekly to confirm bladder filling
and empty rectum. The prescription dose was 77.4 Gy in
1.8 Gy fractions. The coverage goals included V77.4 Gy
100% of the CTV and V77.4 Gy 98% of the PTV. The
maximum dose allowed to the bladder and rectum was
105% (81 Gy). Other constraints for the rectum included
V78 Gy 5% (and V78 Gy <10 cm3), V75 Gy 15%, V70 Gy
25%, V65 Gy 35%, and V50 Gy 60%. Other con-
straints for the bladder included V80 Gy 15%, V75 Gy
25%, V70 Gy 35%, and V65 Gy 50%. All patients
received static field IMRT, typically with 7 fields and
occasionally up to 9. VMAT was not used because our
clinic had not fully implemented VMAT at the time of the
beginning of the trial.
Target localization and tracking
Treatments were delivered using the Calypso Beacons
for localization and continuous, real-time tracking with
the Calypso system. A 2-mm tracking threshold was uti-
lized such that, if the beacons moved more than 2 mm
from their planned position, the therapists intervened to
pause the beam until either the beacons returned to an
acceptable range on their own or the patient was real-
igned. In general, a deviation that persisted for >10 sec-
onds would prompt repositioning.
Table 1 Patient characteristics
Study ProtecT study AIM study PROST-QA cohort
Number enrolled 31 545 64 153
Age (y)
Median 69 69 69
Range 50-82 55-86 47-83
Age group, n (%)
<60 3 (10) 3 (5) 22 (14)
60-69 14 (45) 35 (55) 66 (43)
70 14 (45) 26 (41) 65 (42)
PSA (ng/mL)
Mean 5.8 (2.6) 8.3 (6.2) 6.8 (4.3)
Median 5.79 4.8 6.7 5.8
Range 1.5-11.3 0.6-36.8 0.5-25.8
Group, n (%)
<4 ng/mL 7 (23) 9 (14) 31 (20)
4-10 ng/mL 22 (71) 41 (64) 96 (63)
>10 ng/mL 2 (6) 14 (22) 26 (17)
ADT
Yes 0 21 0
No 31 43 153
Gleason score on biopsy, n (%)
<7 12 (39) 423 (78) 32 (5) 97 (63)
7 19 (61) 108 (20) 26 (41) 56 (37)
>7 0 (0) 14 (3) 6 (9) 0 (0)
Clinical stage, n (%)
T1 20 (65) 429 (79) 32 (50) 123 (80)
T2 11 (35) 116 (21) 31 (48) 30 (20)
T3 0 (0) 0 (0) 1 (2) 0 (0)
Overall cancer risk
Low 12 (39) 15 (23) 61 (40)
Intermediate 19 (61) 41 (64) 88 (58)
High 0 (0) 8 (13) 4 (3)
Other characteristics
Mean BMI (SD) 27.2 (3.9) 28.1 (4.6) 28.5 (5.4)
Mean prostate volume, mL (SD) 45.3 (15.9) 61.0 (25.9) 50.0 (27.0)
ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; SD, standard deviation.
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Patient-reported outcomes
Patients completed the full Expanded Prostate Cancer
Index Composite (EPIC) questionnaire25 prior to radiation
therapy, at Week 5 of radiation therapy, at the last fraction
of radiation therapy, and at 3, 6, 12, 18, and 24 months
after the start of radiation therapy. Three key domains
were assessed: Bowel, urinary, and sexual function. We
compared morbidity to ProtecT, a contemporary, well-
studied cohort of patients who underwent prostate
external beam radiation therapy (EBRT; 3-dimensional
conformal radiation therapy) using conventional PTV
margins.22 Differences between baseline scores and
follow-up EPIC scores were compared between the
Calypso and ProtecT patients. Per previous analyses of
EPIC scores in prostate cancer radiation therapy, a clini-
cally relevant change in quality of life was defined as a
difference from baseline to follow-up that was greater
than half a standard deviation of the baseline value.26
Results
A total of 31 patients were enrolled in our single-
institution study between May 2009 and June 2015. Pa-
tient characteristics can be found in Table 1. A total of
1333 fractions (or treatments) were recorded during this
time. The follow-up time of patients ranged between 12
and 60 months with formal follow-up as part of the study
at 15 months, with a mean follow-up time of 22.45
months.
The mean time of daily treatment was 10 minutes with
a standard deviation of 4.80 minutes (minimum: 4 mi-
nutes; maximum: 71 minutes). Of all treatments, 96.1%
fell within the standard of a 20-minute treatment window.
On average, the PTV only spent 1.76%  1.69% of beam-
on time outside of the 2-mm treatment window.
The average length of a treatment interruption was
34.2 seconds, with an average number of interruptions of
0.30 interruptions per fraction, which is equivalent to an
interruption every 3.39 fractions. Each interruption was
either a pause, during which the prostate returned to
within 2 mm of its planned position on its own, or a
reposition that required a couch position intervention by
the radiation therapist. The average length of a pause was
17.6 seconds, and the median length was 6 seconds. The
average reposition time was 40.5 seconds with a median
of 28.5 seconds. Given the disparity between the mean
and median for both pauses and repositions, the data is
likely skewed by outliers and the median values are more
indicative of common pause and reposition times. These
data are summarized in Table 2.
The greatest variation in displacement or excursion of
the prostate in 3 dimensions was in the superior or inferior
dimension (maximum excursion of the prostate during
beam-on: 1.1  0.9 mm or 0.9  0.9 mm, respectively)
and anterior or posterior dimension (0.7  1.1 mm or
1.3  0.7 mm, respectively). Left or right movement was
found to a lesser degree (0.5  0.6 mm or 0.6  0.6 mm,
respectively). These data are summarized in Table 3 and
Figure 1.
All 31 patients were able to achieve a standard of 98%
PTV coverage at 77.4 Gy, with a mean of 98.4%  0.5%.
The mean rectal volumes at V78 Gy, V75 Gy, and V70 Gy
were 2.7%  1.6%, 8.2%  3.2%, and 14.2%  5.3%,
respectively. The mean bladder volumes at V80 Gy, V75
Gy, and V70 Gy were 1.0%  1.7%, 7.5%  4.2 %, and
10.8%  6.2%, respectively. These data are summarized
in Table 4.
The EPIC questionnaire response rate during the
follow-up was 95%. Three volunteers stopped completing
the questionnaires after 6 to 18 months of follow-up and
others did not fully complete every questionnaire. For
each domain at baseline, our cohort had similar or slightly
lower scores than the comparator group, which indicates a
higher prevalence of baseline symptoms that impair
quality of life. At 6 months, patients demonstrated a
smaller change in scores (ie, better health-related quality
of life) than the comparator group in the bowel, urinary,
and sexual domains, but this change was only statistically
significant in the urinary and sexual domains (P Z .14;
P Z .03; and P < .01, respectively). However, in the
bowel and urinary domains at 12 and 24 months, the
EPIC scores of patients in the ProtecT trial returned closer
to baseline levels, whereas patient scores continued to
decrease or remain stable such that there was no signifi-
cant difference in the EPIC scores of the 2 groups in these
domains. In addition, in the sexual domain, patients
showed significantly smaller follow-up change in scores
at all points of follow-up, but this comparison is
confounded by the use of 6 months of ADT in the ProtecT
trial.
In the ProtecT cohort at 6 months, a clinically mean-
ingful decline is demonstrated in all 3 domains compared
with a clinically meaningful decline only in the bowel
scores in the patient group at that time point. At subse-
quent time points, patients in the ProtecT trial did not
demonstrate a clinically meaningful decline in urinary
symptoms. Table 5 and Figure 2 summarize the patient
reported EPIC scores and changes from baseline for pa-
tients and the radiation therapy arm of the ProtecT trial.
Table 2 Interruption length and breakdown
Interruption
Time (s)
Pause
Time (s)
Reposition
Time (s)
Mean 34.2 17.55 40.51
SD 33.79 37.56 51.21
Median 19.68 6 28.5
Minimum 1 1 2
Maximum 601 301 501
SD, standard deviation.
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Discussion
In the recent ProtecT trial, EBRT had little effect on
urinary continence, a stable long-term effect on sexual
function, and a worsening effect on bowel function (with
recovery) when compared with prostatectomy.22 Of note,
all men in the radiation arm of this trial also received
ADT. In addition, the radiation technique was 3-
dimensional conformation radiation therapy. To improve
EBRT’s toxicity profile, many efforts have been made to
improve radiation delivery techniques, including inter-
and intrafraction monitoring, to decrease dose delivery to
organs at risk.
A common concern about smaller PTV margins is
intrafraction motion. There is significant time between
obtaining on-board kV imaging and the completion of the
daily radiation fraction with multiple field IMRT plans,
which leaves more time for intrafraction motion. Using
the same technology, Shelton et al. in their study of 37
patients demonstrated that treatment time was the stron-
gest predictor of observed displacements, and that VMAT
was associated with reduced motion.23 Langen et al. re-
ported similar findings that the likelihood of prostate
gland movement increased with time, and emphasized the
importance of initiating treatment quickly after initially
imaging the patient and minimizing overall time of
treatment to decrease the likelihood of prostate drift.13 In
a comparison of VMAT with electromagnetic tracking to
IMRT with and without electromagnetic tracking, Hall
et al. found that VMAT was associated with a decreased
time of delivery per treatment.24 In addition, the re-
searchers found that using VMAT with electromagnetic
tracking did not cause a significantly different treatment
time compared with previous methods overall.24 Hall
et al. had an average treatment time of 13.81 minutes with
VMAT with Calypso tracking.24
Our data show a lesser mean treatment time of
10.04.80 minutes using the same technologies with
IMRT. We suspect that by using VMAT, treatment times
would be even shorter. In addition, our data show
encouraging reproducibility, with 96.1% of all treatments
falling within a standard treatment time of 20 minutes.
Our data confirm and support that using Calypso tracking
is time efficient and reproducible.
Our study is one of the first to demonstrate minimal
disruption to daily treatments using this new technology.
Langen et al. had only 17 of 550 fractions (3.1%) with
interventions; however, their protocol did not dictate any
interventions on the basis of observed prostate displace-
ment.13 In a similar study for patients undergoing prostate
SBRT with Calypso tracking, Lovelock et al. demon-
strated an average of 1.74 interventions or fraction
required, with an increase in time of dose delivery of
approximately 65 seconds.12 Even with strict margins <2
mm to require an intervention, we only required 1 inter-
vention every 3.39 fractions, with a mean added time of
34.2 seconds per intervention. Each pause (ie, self-return
of the prostate to within 2 mm) was a median of 6 seconds
long, and each reposition was a median of 28.5 seconds in
duration. Pauses do not appear to contribute significantly
Table 3 Maximum prostate excursion or displacement
during beam-on
Displacement (mm)
Left Right Superior Inferior Anterior Posterior
Mean 0.5 0.6 1.1 0.9 0.7 1.3
SD 0.6 0.6 0.9 0.9 1.1 0.7
Median 0.5 0.6 1.0 0.9 0.4 1.3
Minimum e1.1 e1.2 e1.4 e1.2 e4.0 e1.1
Maximum 6.7 6.0 10.7 11.5 11.4 4.5
SD, standard deviation.
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Figure 1 Patient Mean Prostate Excursion/Displacement
During Beam-On.
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to treatment time, but repositions tend to be slightly
longer.
In addition, we noted that in a few rare instances, re-
positions required anywhere from to 5 to 8 minutes and
were likely due to rectal gas, which may have distorted
the prostate and required a CBCT and repositioning.
However, given the relatively low rate of interventions (1
intervention every 3.39 fractions) and the relatively small
amount of time added on average by either an intervention
or pause, our data show that Calypso tracking reliably
provides minimal disruption to daily treatments and
overall time of treatment. Implementing the Calypso
tracking worked seamlessly in our clinic workflow and
did not negatively impact patient care.
Many previous studies have tracked prostate intra-
fraction motion and its displacement or excursion has been
well described in the literature.8,13-17,20,23 Mayyas et al.
used Calypso tracking and found standard deviations for
intrafraction prostate motion of 1.3, 1.5, and 0.6 mm (2
standard deviation values would be 2.6, 3.0, and 1.2mm) in
the anterior or posterior, superior or inferior, and left or right
directions, respectively, in a study of 27 patients.15
Shelton et al. also found that shifts were greater in the
anterior or posterior and superior or inferior dimensions
and were likely related to organ motion, and left or right
motion was less and likely related to patient motion.23
Langen et al. described that the prostate’s displacement
in all directions was >3 mm for 13.6% of the time, and
>5 mm for 3.3% of the time on average.13 Lin et al.
looked at respiratory-induced prostate motion and found
an oscillatory pattern of the prostate in the anterior or
posterior and superior or inferior directions, with 99% of
patients showing an average respiratory-induced motion
between 0.2 and 2.0 mm.19
In our study, we found prostate motion to be similar to
slightly lower than what has generally been described
Table 4 Dosimetric data
PTV Rectum Bladder
V77.4 (98%) V78 (5%) V75 (15%) V70 (25%) V80 (15%) V75 (25%) V70 (35%)
Mean 98.4% 2.7% 8.2% 14.2% 1.0% 7.5% 10.8%
SD 0.5% 1.6% 3.2% 5.3% 1.7% 4.2% 6.2%
Minimum 98.0% 0.0% 1.3% 3.5% 0.0% 2.5% 3.7%
Maximum 99.9% 6.4% 14.9% 23.0% 7.8% 16.6% 27.0%
PTV, planning target volume; SD, standard deviation; Vx, coverage goal of x Gy.
Table 5 Patient-reported morbidity comparison (EPIC Scoresa)
Domain Our Study (n Z 31) ProtecT (n Z 545) P-value
Score,
mean (SD)
Mean differenceb
(95% CI)
Clinically
meaningful
declinec
Score,
mean
(SD)
Mean differenceb
(95% CI)
Clinically
meaningful
declinec
Bowel
Baseline 94.1 (6.6) e e 94.8 (6.9) e e e
6 mo 90.5 (12.2) e3.6 (e8.5 to 1.3) Yes 86.3 (16.0) e8.5 (e10.4 to e6.6) Yes .14
12 mo 87.8 (14.2) e6.3 (e11.8 to e0.8) Yes 90.5 (12.2) e4.3 (e5.8 to e2.8) Yes .47
24 mo 88.1 (13.7) e6.0 (e11.4 to e0.6) Yes 89.3 (12.8) e5.5 (e7.0 to e4.0) Yes .86
Urinary
Baseline 88.9 (10.6) e e 93.2 (8.3) e e e
6 mo 87.2 (13.3) e1.7 (e7.7 to 4.3) No 84.7 (13.8) e8.5 (e10.3 to e6.7) Yes .03
12 mo 85.2 (14.4) e3.7 (e10.0 to 2.6) No 91.9 (9.0) e1.3 (e2.7 to 0.1) No .36
24 mo 84.3 (14.4) e4.6 (e10.9 to 1.7) No 91.4 (9.8) e1.8 (e3.2 to e0.4) No .31
Sexual
Baseline 48.9 (31.8) e e 63.6 (23.1) e e e
6 mo 41.1 (30.1) e7.8 (e23.2 to 7.6) No 31.9 (27.1) e31.7 (e35.8 to e27.6) Yes < .01
12 mo 36.7 (26.2) e12.2 (e26.7 to 2.3) No 43.2 (27.6) e20.4 (e24.5 to e16.3) Yes < .01
24 mo 41.7 (29.2) e7.2 (e22.4 to 8.0) No 43.4 (25.9) e20.2 (e24.1 to e16.3) Yes < .01
CI, confidence interval; EPIC, Expanded Prostate Cancer Index Composite; SD, standard deviation.
a Scores range from 0 to 100, and higher scores indicate better patient-reported quality of life.
b Change from baseline to follow-up, calculated from within-patient differences.
c Mean difference >0.5 SD from baseline value.
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previously in the literature. This is in line with research by
Bell et al. in a smaller study of only 3 patients, with
findings of mean intrafraction motion of 0.2 cm in all
directions.8 Additionally, the prostate spent only 1.76% of
the time outside of our planned tracking constraint of 2
mm. These are strong indicators that 3 mm margins are
feasible and safe.
We would expect that a decrease in PTV margin would
lead to a decrease in normal tissue toxicity. Michalski
et al. showed that IMRT was associated with a reduction
in acute GI and GU toxicity, and that keeping V70 Gy and
V75 Gy at <15% and <10%, respectively, was associated
with lower rates of GI toxicity.2 Our V70Gy of 14.2% and
V75 Gy of 8.2% fell within these margins and would thus
be associated with a reduction in toxicities as described by
Michalski et al.2 Zelefsky et al. found that, with inter-
fraction monitoring using fiducial markers versus a
similar non-IGRT cohort, there was significant reduction
in late urinary toxicity.9 Although previous studies have
focused on rectal toxicity, our bladder dosimetry data at
V80 Gy, V75 Gy, and V70 Gy show values that are in line
with modern dosimetry standards to decrease GU
toxicity.21
Patient-reported, health-related outcomes measured by
EPIC questionnaire were generally improved or similar
when compared with those of the ProtecT radiation
therapy arm. Most notably, at 6 months of follow-up, the
urinary domain was significantly improved in our study,
and changes in sexual function scores remained signifi-
cantly better compared with those of ProtecT. Although
the initial decrements were smaller in our study, the
ProtecT radiation therapy cohort showed a trend to return
closer to baseline while our study showed stability/small
decrements in bowel and urinary scores throughout 24
months of follow-up.
Modeling studies have previously estimated that 3-mm
PTV margins in prostate cancer can decrease rectal tox-
icities by reducing volume of acute normal tissue damage,
which can predict late tissue damage.27,28 This may
suggest that the decreased short-term morbidity observed
in our study may translate into long-term improvements in
morbidity that we were unable to observe in our smaller
patient group.
Some observed differences in EPIC scores between
our patients and those in the ProtecT trial may be
related to differences in technique, lower doses used in
the ProtecT trial (74 Gy in 37 fractions), and the fact
that all men in the radiation arm of the ProtecT trial
were treated with short-term ADT. An ADT-related
reduction in prostate size could lead to improved EPIC
scores.
Our analysis of patient-reported, health-related out-
comes compared with those of the ProtecT radiation
therapy arm is consistent with previous analyses of our
cohort to the AIM and Prost-QA studies,26,31 where
pre- and post-treatment EPIC-26 survey scores for
bowel, urinary irritation/incontinence, and sexual func-
tion were compared.32 A clinically meaningful decline
was demonstrated in 2 domains in our study, 1 domain
in the AIM study, and 3 domains in the Prost-QA
cohort study (Table 6). Furthermore, mean decrements
between pre- and posttreatment scores were significantly
lower in the AIM study compared with those in our
cohort in the urinary irritation domain (P Z .0009).
Our cohort’s results were most similar to those of Prost-
QA patients, but worse than the AIM non-neoadjuvant
hormonal therapy study cohort in the urinary irritation
domain.
Upcoming areas of interest include hypofractionation
of localized prostate cancer treatment because prospective
trials, such as the Conventional versus Hypofractionated
High-Dose Intensity Modulated Radiotherapy for Prostate
Cancer trial, have shown noninferiority of hypofractio-
nated treatment and the possibility to decrease
94.1
90.5
87.8
88.1
94.8
86.3
90.5
89.3
85
90
95
0 6 12 18 24
E
PI
C
 S
co
re
Months
Bowel
Our Study Bowel ProtecT Bowel
88.9
87.2
85.2 84.3
93.2
84.7
91.9 91.4
80
85
90
95
0 6 12 18 24
E
PI
C
 S
co
re
Months
Urinary
Our Study Urinary ProtecT Urinary
48.9 41.1
36.7
41.7
63.6
31.9
43.2 43.4
25
35
45
55
65
0 6 12 18 24
E
PI
C
 S
co
re
Months
Sexual
Our Study Sexual ProtecT Sexual
Figure 2 EPIC Scores.
636 A.R. Chaurasia et al Advances in Radiation Oncology: OctobereDecember 2018
toxicities.29,30 Further areas of study include the study of
intrafraction monitoring in the setting of hypofractionated
treatments and prostate SBRT. Concern remains about
late toxicities in these treatment regimens, but one way to
help reduce this may be with smaller PTV margins and
tighter rectal or bladder constraints.
The limitations of our study include the relative small
size of the patient population and the fact that the study
was performed at a single institution. Future studies that
incorporate larger patient populations and more treatment
centers may point toward more generalizable ways of
incorporating Calypso tracking into routine dosimetric
planning and daily treatments.
Conclusions
Our data confirm and support that using Calypso
tracking is reliable to provide minimal disruption to daily
treatments and overall time of treatment, with the PTV
only moving outside of a 3-mm margin <2% of the time.
IMRT with Calypso tracking presents an effective way to
track the prostate in real time. Using 3-mm PTV margins
provides adequate dosimetric coverage while also mini-
mizing GU and GI toxicity. Our decreased, observed,
short-term morbidity may translate into long-term im-
provements in morbidity that we were unable to observe
in our smaller patient group. Hypofractionation and
prostate SBRT are ongoing areas of research for which
Calypso tracking with reduced PTV margins may serve as
an important tool to improve accuracy and minimize
toxicity.
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